Recently, the Category 1 innovative drug Vebreltinib Enteric Capsules of Beijing Pearl Biotechnology Limited Liability Company was approved for marketing with conditions by China NMPA. This drug is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition factor (MET) exon 14 mutation.

Vebreltinib is a tyrosine kinase inhibitor of cell mesenchymal epithelial transition factor (c-MET) receptor that can inhibit the proliferation of tumor cells with high c-MET expression. The marketing of this drug provides a new treatment option for NSCLC patients with MET exon 14 mutation.